Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O43556
UPID:
SGCE_HUMAN
Alternative names:
-
Alternative UPACC:
O43556; B2R8N2; D6W5Q8; E9PF60; G5E9K6; Q6L8P0; Q75MH8; Q8NFG8; Q8WW28
Background:
Epsilon-sarcoglycan, encoded by the gene with accession number O43556, is a crucial component of the sarcoglycan complex. This complex is part of the larger dystrophin-glycoprotein complex, linking the F-actin cytoskeleton to the extracellular matrix. This linkage is vital for the integrity of muscle tissue.
Therapeutic significance:
Dystonia 11, myoclonic, a form of dystonia characterized by involuntary muscle contractions and alleviated by alcohol, is associated with variants in the epsilon-sarcoglycan gene. Understanding the role of epsilon-sarcoglycan could lead to novel therapeutic strategies for this condition.